期刊文献+

基于案例分析的新药研发课程教学 被引量:6

Teaching of New Drug Research and Development Courses Based on Case Analysis
下载PDF
导出
摘要 新药研发课程是药学研究生课程体系的重要组成部分,有力支撑着高层次药学人才培养目标的达成。基于案例分析的新药研发课程,立足于新药研发产业链,贯穿药物发现、临床前研究、临床研究以及新药申报整个流程;采用以研发方法和技术为基础、Palbociclib研发案例为素材、课堂互动讨论为手段、像R&D人员一样思考为目标的教学方式;帮助学生在掌握新药研发知识体系的基础上,对新药研发流程建立形象化、立体化的认知,激发学生兴趣,主动开展研究性学习。 The new drug research and development course is an important part of the pharmacy graduate curriculum system,which strongly supports the achievement of the goal of high-level pharmacy talent training.The new drug R&D course based on case analysis,based on the new drug R&D industry chain,runs through the entire process of drug discovery,preclinical research,clinical research and new drug application;R&D methods and technologies is used as the basis,Palboclib R&D cases is used as the material,and classroom interactive discussions is used as the the teaching method with the goal of thinking like R&D talents.The purpose of this is to help students to establish a visual and three-dimensional cognition of the new drug research and development process on the basis of mastering the new drug research and development knowledge system,and stimulate students interest to actively carry out research-based learning.
作者 卢闻 曾爱国 张杰 Lu Wen;Zeng Aiguo;Zhang Jie(School of Pharmacy,Health Science Center,Xi'an Jiaotong University,Xi'an 710061,China)
出处 《药学教育》 2022年第1期44-48,共5页 Pharmaceutical Education
关键词 案例教学法 新药研发课程 教学实践 case teaching method new drug R&D course teaching practice
  • 相关文献

参考文献8

二级参考文献66

  • 1陈静,储文功,顾文华.建立《药事管理学》案例库的几点思考[J].药学实践杂志,2006,24(4):242-243. 被引量:24
  • 2陈军,蔡宝昌.案例教学法在药剂学教学中的运用[J].药学教育,2007,23(6):31-33. 被引量:66
  • 3Lim S,Kaldis P.CDKs cyclins and CKIs:Roles beyond cell cycleregulation[J].Development,2013,140(15):3079-3093.
  • 4Asghar U,Witkiewicz A K,Turner N C,et al.The history and future of targeting cyclin-dependent kinases in cancer therapy[J].Nat Rev Drug Discov,2015,14(2):130-146.
  • 5Cicenas J,Kalyan K,Sorokinas A,et al.Highlights of the latest advances in research on CDK inhibitors[J].Cancers,2014,6(4):2224-2242.
  • 6Canavese M,Santo L,Raje N.Cyclin dependent kinases in cancer:potential for therapeutic intervention[J].Cancer Biol Ther,2012,13(7):451-457.
  • 7FDA.palbociclib说明书[EB/OL].(2015-02-03)[2016-05-11].http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207103s000lbl.pdf.
  • 8Cadoo KA,Gucalp A,Traina T A.Palbociclib:an evidence-based review of its potential in the treatment of breast cancer[J].Breast Cancer:Targets and Therapy,2014,6:123-133.
  • 9Finn R S,Dering J,Conklin D,et al.PD 0332991,a selective cyclin D kinase 4/6 inhibitor,preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro[J].Breast Cancer Res,2009,11(5):R77.
  • 10沃尼尔·朗伯有限责任公司.2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮.中国专利.CN101906104B[P].2013-06-05.

共引文献38

同被引文献59

引证文献6

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部